All Drug Targets articles – Page 7
-
NewsOral arginine reduces harmful amyloid in Alzheimer’s models
A naturally occurring amino acid commonly found in supplements has reduced harmful amyloid build-up and eased symptoms in animal models of Alzheimer’s disease.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
-
ArticleAdvancing disease biomarker research with EV multiplex profiling
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
-
NewsNew stealth CRISPR method reduces immune interference in tumours
Researchers have developed a novel CRISPR method that evades the immune system in mice, allowing scientists to study tumour growth and metastasis more accurately.
-
ArticleAI and policy reform set to reshape UK drug development
BCG’s Chris Meier outlines how advances in AI and new UK policies could accelerate drug development, streamline clinical trials and strengthen the country’s life sciences sector.
-
NewsNew CAR-T cell therapy capable of destroying glioblastoma cells
A new CAR-T treatment developed in Switzerland has shown striking early success against glioblastoma, one of the deadliest brain cancers, and is now moving towards human trials.
-
NewsRecycled nuclear fuel to power new cancer treatments in the UK
The UK is set to turn recycled nuclear fuel into new cancer treatments, thanks to a £18.8 million investment in a project using lead-212 to develop Targeted Alpha Therapies.
-
NewsDeepTarget tool helps identify secondary cancer drug targets
A new computational tool, DeepTarget, is demonstrating context-specific targets and repurposing opportunities, showing that what may be a side effect in one patient could serve as a treatment in another.
-
NewsFGD3 protein enhances breast cancer therapies
Scientists have identified a little-known protein, FGD3, that can boost the power of key breast cancer treatments by helping drugs rupture tumour cells and activate the immune system.
-
NewsNew framework enhances reliability of virtual cell models
Shift Bioscience have announced new research revealing that AI-driven virtual cell models perform far better than previously thought when assessed with correctly calibrated metrics.
-
NewsHow a psychedelic found in mushrooms could help fight alcoholism
Scientists have discovered that psilocin – the compound produced in the body from the psychedelic found in magic mushrooms – may reduce alcohol consumption by calming activity in brain regions linked to stress.
-
NewsTRβ receptor could be key to slowing prostate cancer
A thyroid hormone receptor may play a key role in prostate cancer growth, offering a potential new target for treating aggressive forms of the disease.
-
NewsProtein FSP1 found to help melanoma survive in lymph nodes
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer cells spreading to lymph nodes depend on a protein called FSP1 to avoid cell death.
-
NewsBVRA enzyme may slow down Alzheimer’s progression
New research from Johns Hopkins Medicine reveals that the enzyme BVRA protects brain cells from oxidative stress, allowing for potential new methods for treating neurodegenerative diseases like Alzheimer’s.
-
ArticleMeet WRPRFa: the precision peptide changing how we study pain
A newly developed peptide, WRPRFa, is giving scientists a clearer view of how the acid-sensing ion channel (ASIC3) drives pain signalling.
-
NewsTargeting fibroblasts could lead to new heart failure therapies
Long considered structural support cells, a new research study has discovered how fibroblasts actively worsen heart failure by disrupting heart muscle function, which could lead to new therapeutic strategies for heart failure.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part II
Part II shows that the predictive validity crisis can be solved by rethinking how the industry chooses models, measures outcomes and integrates systems. Success stories from Vertex, Regeneron and AstraZeneca illustrate how aligning biology, measurement and strategy can reverse decades of declining productivity.
-
NewsPulmonary fibrosis: new drug slows and reverses lung scarring
Researchers have identified a key cellular mechanism that drives pulmonary fibrosis and successfully blocked it in mice, reducing lung scarring.
-
ArticleHow real-world data is accelerating drug discovery
Vish Srivastava considers the benefits of expanding the role of real-world data in drug discovery to provide improved therapies, faster and with greater success.
-
NewsImproving brain resilience: Rab proteins and future treatments
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.